Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis

Circulating Vitamin D and Overall Survival in Breast Cancer Patients: A Dose-Response Meta-Analysis of Cohort Studies

Integrative Cancer Therapies First Published June 7, 2017 Research Article

Kejia Hu, MD, David Frederick Callen, PhD, Jiayuan Li, PhD, ...

* Cancer risk reduced 65 percent by vitamin D levels greater than 40 nanograms – April 2016* Breast Cancer rate reduced 72 percent by vitamin D gene polymorphism CYP24A1 – Nov 2014* Breast Cancer severity strongly associated with low vitamin D – May 2017* Breast Cancer outcomes much better if higher vitamin D levels – Nov 2016* Breast Cancer was 4.6 times more likely if have a poor Vitamin D Receptor – Dec 2016* Note: genes to be far more important than levels of vitamin D, genes can be influenced* The “Deadly Breast Cancer Gene” Is A Myth, Lancet Study Confirms – Jan 2018 has the following* 1. Overview Breast Cancer and Vitamin D contains the following summary and sections{include} 1. Cancers have learned to reduce Vitamin D Receptor activation to reduce Vitamin D from getting to cellsItems in both categories Breast Cancer and 1. F00:Vitamin D Receptor {category}---The risk of 44 diseases at least double with poor Vitamin D Receptor as of Oct 2019 * Omega-3,  Magnesium, Zinc,  Quercetin,  non-daily Vit D,  Curcumin, intense exercise,   Ginger,   Essential oils, etc**  Note: The founder of Vitamin D Life uses 10 of the 12 known VDR activators

📄 Download the PDF from Vitamin D Life

Studies have shown that vitamin D could have a role in breast cancer survival; however, the evidence of the relationship between patients’ vitamin D levels and their survival has been inconsistent. This meta-analysis explores possible dose-response relationships between vitamin D levels and overall survival by allowing for differences in vitamin D levels among populations of the various studies. Studies relating vitamin D (25-OH-D [25-hydroxyvitamin D]) levels in breast cancer patients with their survival were identified by searching PubMed and Embase. A pooled HR (hazard ratio) comparing the highest with the lowest category of circulating 25-OH-D levels were synthesized using the Mantel-Haenszel method under a fixed-effects model. A two-stage fixed-effects dose-response model including both linear (a log-linear dose-response regression) and nonlinear (a restricted cubic spline regression) models were used to further explore possible dose-response relationships.

Six studies with a total number of 5984 patients were identified. A pooled HR comparing the highest with the lowest category of circulating 25-OH-D levels under a fixed-effects model was 0.67 (95% confidence interval = 0.56-0.79, P < .001). Utilizing a dose-response meta-analysis, the pooled HR for overall survival in breast cancer patients was 0.994 (per 1 nmol/L), P for linear trend < .001. At or above a 23.3 nmol/L threshold, for a 10 nmol/L, 20 nmol/L, or 25 nmol/L increment in circulating 25-OH-D levels, the risk of breast cancer overall mortality decreased by 6%, 12%, and 14%, respectively.

There was no significant nonlinearity in the relationship between overall survival and circulating 25-OH-D levels. Our findings suggest that there is a highly significant linear dose-response relationship between circulating 25-OH-D levels and overall survival in patients with breast cancer. However, better designed prospective cohort studies and clinical trials are needed to further confirm these findings.